| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | 2A9; PRA; 5B10; CABP; CACY |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human S100A6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于S100A6抗体的文献摘要概括：
1. **文献名称**: *S100A6 antibody modulates tumor progression through the RAGE-NF-κB pathway*
**作者**: Leclerc E. et al.
**摘要**: 该研究利用特异性S100A6抗体，发现S100A6通过与细胞表面受体RAGE相互作用激活NF-κB通路，促进胰腺癌细胞迁移和侵袭，提示其作为癌症治疗靶点的潜力。
2. **文献名称**: *Development of a monoclonal antibody against S100A6 for immunohistochemical diagnosis*
**作者**: Tanaka M. et al.
**摘要**: 研究团队开发了一种高灵敏度和特异性的单克隆S100A6抗体，验证其在结直肠癌组织中的表达，证实S100A6高表达与患者不良预后显著相关。
3. **文献名称**: *S100A6 antibody reveals its role in neuronal apoptosis during Alzheimer's disease*
**作者**: Smith J. et al.
**摘要**: 通过S100A6抗体标记发现，阿尔茨海默病模型中S100A6在神经元中异常聚集，激活凋亡通路，提示其参与神经退行性病变的分子机制。
4. **文献名称**: *Antibody-based detection of S100A6 in serum as a biomarker for melanoma progression*
**作者**: González R. et al.
**摘要**: 研究使用ELISA结合S100A6多克隆抗体，验证血清S100A6水平可作为黑色素瘤转移的早期诊断标志物，灵敏度达85%，优于传统标志物。
*注：以上文献信息为示例性质，具体内容需根据实际发表论文调整。*
S100A6. also known as calcyclin, is a calcium-binding protein belonging to the S100 family, which comprises over 20 members involved in diverse cellular processes. S100A6 is encoded by the *S100A6* gene on human chromosome 1q21 and functions as a homodimer or heterodimer with other S100 proteins. It regulates intracellular activities such as cell cycle progression, differentiation, cytoskeletal dynamics, and apoptosis by interacting with target proteins like calmodulin, annexins, and CacyBP/SIP. S100A6 is expressed in various tissues, including the brain, pancreas, and smooth muscle, and its expression is often upregulated in cancers, such as melanoma, pancreatic adenocarcinoma, and colorectal carcinoma, correlating with tumor progression and metastasis.
Antibodies against S100A6 are essential tools for detecting its expression and localization in cells and tissues. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study S100A6's role in physiological and pathological contexts. Commercially available S100A6 antibodies include monoclonal and polyclonal variants, often validated for specificity using knockout controls or recombinant proteins. In research, S100A6 antibodies have helped uncover its potential as a biomarker for certain cancers and inflammatory conditions. For example, elevated S100A6 levels in serum or tissue samples may indicate disease severity or prognosis. However, variability in antibody performance across applications necessitates careful validation to ensure reliability. Ongoing studies continue to explore S100A6's therapeutic relevance, particularly in modulating calcium signaling pathways in disease.
×
